Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 4/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213420 | 0.91 | RXRA (0.33) | MRGPRX4NSD2ESR1POLBAPEX1 | |
| SCHEMBL213497 | 0.90 | RXRA (0.41) | MRGPRX4KDM4E | |
| SCHEMBL214551 | 0.89 | NSD2 (0.39) | MRGPRX4NSD2ESR1POLBAPEX1 | |
| SCHEMBL215638 | 0.87 | MRGPRX4 (0.35) | MRGPRX4NSD2ESR1POLBAPEX1 | |
| SCHEMBL216678 | 0.87 | MRGPRX4 (0.38) | MRGPRX4KDM5AKDM4CKDM5BKDM4A | |
| SCHEMBL213839 | 0.86 | MCL1 (0.37) | MRGPRX4KDM5AKDM4CKDM5B | |
| SCHEMBL213488 | 0.86 | MRGPRX4 (0.34) | MRGPRX4NSD2ESR1POLBAPEX1 | |
| SCHEMBL215487 | 0.86 | MCL1 (0.37) | MRGPRX4KDM5AKDM4CKDM5B | |
| SCHEMBL212920 | 0.86 | MRGPRX4 (0.34) | MRGPRX4KDM5AKDM4CKDM5B | |
| SCHEMBL214674 | 0.86 | MRGPRX4 (0.34) | MRGPRX4KDM5AKDM4CKDM5BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | claimed |
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | claimed |
| US-20100041708-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | claimed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | claimed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | claimed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7235667-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-26 | — | — | US | disclosed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | disclosed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | PTGER1, PTGER2, PTGES | MRGPRX4 686/4885EPHX2 2022/4885NSD2 160/4885 |
| US-20100041708-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION | PTGER1, PTGER2, PTGES | MRGPRX4 747/4885EPHX2 1368/4885NSD2 220/4885 |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | PTGER1, PTGER2, PTGES | MRGPRX4 907/4885EPHX2 1955/4885NSD2 147/4885 |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | MRGPRX4 875/4885EPHX2 115/4885NSD2 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.